Jasbir Seehra - Feb 23, 2024 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Feb 23, 2024
Transactions value $
$0
Form type
4
Date filed
2/23/2024, 05:07 PM
Previous filing
Feb 15, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Award $0 +125K $0.00 125K Feb 23, 2024 Common Stock 125K $63.61 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction involves the Reporting Person's receipt of an option grant. The shares subject to the option shall vest upon the achievement of specified performance criteria, subject to the Reporting Person continuing to provide service through each such date.